Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

✍ Scribed by Saburo Onishi; Toshiji Saibara; Masanao Fujikawa; Hiroshi Sakaeda; Yasushi Matsuura; Yoichi Matsunaga; Yasutake Yamamoto

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: English
• Weight: 591 KB
• Volume: 10
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.1840100318

✦ Synopsis

Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokineactivated killer cells plus recombinant interleukin 2. Patients received 16 pg per day of recombinant interleukin 2 consecutively (for 14 to 64 days), from Day 7 prior to the first leukapheresis, and received lo9 to 10" lymphokine-activated killer cells once or twice per week intravenously; the lymphokine-activated killer cells had been generated from mononuclear cells obtained through leukapheresis. Preadministration of recombinant interleukin 2 prior to the first leukapheresis resulted in a remarkable increase of lymphokine-activated killer activity in seven of nine cases in whom lymphokine-activated killer activity had been poorly inducible even at high concentrations of recombinant interleukin 2. At the end of the treatment, liver tumor regression (34 and 63%, respectively, of two-dimensional size) was observed in two of two patients with a solitary tumor; no increase of liver tumor size was observed in seven patients with massive or multiple tumors, and no changes in the size or number of pulmonary metastatic tumors in any patients were observed. More than a